Bristol Myers Squibb (CELG-RI) Restructuring Costs (2009 - 2013)

Bristol Myers Squibb has disclosed Restructuring Costs across 5 years of filings, most recently posting $33.0 million for Q1 2013.

• In Q1 2013, Restructuring Costs rose 50.0% year-over-year to $33.0 million; the TTM figure through Mar 2013 stood at $164.0 million (up 137.68% YoY), while the FY2012 annual figure was $174.0 million, up 50.0% from the prior year.
• Restructuring Costs declined to $33.0 million in Q1 2013, from $103.0 million in the prior quarter.
• Over the last five years, Restructuring Costs for CELG-RI reached as high as $103.0 million in Q4 2012 and fell as low as $1.0 million in Q1 2011.
• The 5-year median for Restructuring Costs is $20.0 million (2012), against an average of $27.9 million.
• Annual changes were most pronounced in 2011 — Restructuring Costs sank 90.91% — and 2012, when it surged 2100.0%.
• A 5-year view of Restructuring Costs shows it stood at $35.0 million in 2009, then surged by 80.0% to $63.0 million in 2010, then sank by 61.9% to $24.0 million in 2011, then jumped by 329.17% to $103.0 million in 2012, then sank by 67.96% to $33.0 million in 2013.
• According to Business Quant data, Restructuring Costs over the past three periods registered $33.0 million, $103.0 million, and $8.0 million for Q1 2013, Q4 2012, and Q3 2012 respectively.